Efficacy of the combined therapy with bortezomib, dexamethasone and zoledronic acid in the treatment of multiple myeloma

高珊,付蓉,关晶,王婷,邵宗鸿

DOI: https://doi.org/10.3781/j.issn.1000-7431.2009.06.019

2009-01-01

Tumor

Abstract:Objective:To evaluate the efficacy and safety of bortezomib plus dexamethasone and zoledronic acid(VDZ) in the treatment of multiple myeloma(MM).Methods:Ten MM patients received VDZ regimen in a 28-day cycle.All the patients received 1 to 8 cycles of chemotherapy.International Uniform Response Criteria for MM was used to evaluate the clinical response of the patients.The adverse events were graded according to the guide of National Cancer Institute Common Terminology Criteria for Adverse Events(NCICTCAE,version 3.0).Results:The median follow-up duration was 11.6(1 to 27) months.The total response rate was 80%(8/10).Among them,4 patients had complete response,3 patients achieved very good partial response,and 1 patient had partial response.One patient was in stable disease and one patient requested to stop the chemotherapy before evaluation.The main adverse events included peripheral neuropathy,gastrointestinal symptoms,fatigue,and thrombocytopenia and leucopenia at different degrees.All the adverse reactions were ameliorated after treatment.Conclusion:The VDZ regimen was effective in the treatment of either newly-diagnosed or refractory MM patients.Although VDZ regimen induced some kinds of adverse reactions,the adverse events could be ameliorated after treatment.